Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | EVP, Chief Dev. Officer | February 28, 2022 | March 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Karyopharm Therapeutics Inc.
Report date February 28, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 168,290 |
Ending reported balance
After 2022-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-28 · Grant · Acquired 68,250 · Balance 169,953 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. Row 2 · 2022-02-28 · Sale · Disposed 1,663 · Balance 168,290 F2: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.41, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.33 · Expires 2032-02-27 | Direct | 90,000 |
Reported balance
After 2022-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-28 · Grant · Acquired 90,000 · Balance 90,000 F4: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.
F2: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.41, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2022 Filed Mar 2, 2022 20:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $10.33 | $0.00 |
DisclosureSEC source: 0001209191-22-014629 · doc4.xml · derivative · entry 3 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-27 F4 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 20:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,663 | $10.24 | $17,025.13 |
DisclosureSEC source: 0001209191-22-014629 · doc4.xml · nonDerivative · entry 2 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,290 F2 · shares: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.41, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 20:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 68,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014629 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,953 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,929 | $12.12 | $35,509.44 |
DisclosureSEC source: 0001209191-22-011643 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,703 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 22:26 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,991 | $9.86 | $19,635.24 |
DisclosureSEC source: 0001209191-22-008128 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,632 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. F3 · balance_after: Includes 861 shares and 1,323 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2021 and October 31, 2021, respectively. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 59,968 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015484 · doc4.xml · derivative · entry 2 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,968 Underlying: Common Stock · 59,968 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 22,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015484 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,439 F1 · shares: Represents the award of Restricted Stock Units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 36,300 RSUs previously reported in Table II, and 46,126 shares of common stock. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 01:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,887 | $14.83 | $42,817.67 |
DisclosureSEC source: 0001209191-21-012967 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,126 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:47 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 9,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011490 · doc4.xml · derivative · entry 3 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,350 Underlying: Common Stock · 9,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F4 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F4 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:47 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 9,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-011490 · doc4.xml · nonDerivative · entry 2 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 23:47 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,046 | $15.52 | $31,751.87 |
DisclosureSEC source: 0001209191-21-011490 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,338 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 01:33 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 5,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009079 · doc4.xml · derivative · entry 2 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,950 Underlying: Common Stock · 5,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F3 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 01:33 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 5,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009079 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · EVP, Chief Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F2 · balance_after: Includes 646 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:26 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,974 | $20.00 | $39,480.00 |
DisclosureSEC source: 0001209191-20-028271 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,088 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 996 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:57 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,975 | $16.48 | $49,033.65 |
DisclosureSEC source: 0001209191-20-011696 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,066 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 19, 2020 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 9,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010756 · doc4.xml · derivative · entry 2 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,025 Underlying: Common Stock · 9,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F3 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date. F3 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 38,700 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 9,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-010756 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F2 · balance_after: Includes 4,633 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:19 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 22,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007510 · doc4.xml · derivative · entry 2 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,600 Underlying: Common Stock · 22,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:19 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 60,600 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007510 · doc4.xml · derivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,600 Underlying: Common Stock · 60,600 shares Expires 2030-02-04 F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:27 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 38,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011082 · doc4.xml · derivative · entry 2 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Stock · 38,700 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 15, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:27 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 102,800 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001209191-19-011082 · doc4.xml · derivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,800 Underlying: Common Stock · 102,800 shares Expires 2029-02-14 F1 · derivative.exercise_date: This option was granted on February 15, 2019. The shares underlying this option vest as to 25% of the shares on February 15, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:31 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-18-005383 · doc4.xml · derivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: This option was granted on January 24, 2018. The shares underlying this option vest as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 21:04 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 4,958 | $11.25 | $55,755.19 |
DisclosureSEC source: 0001209191-17-059945 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,733 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 6, 2017 and November 7, 2017 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| November 05, 2017 Filed Nov 6, 2017 21:09 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-059399 · doc4.xml · derivative · entry 2 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F2 · derivative.exercise_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016. The remaining 50% of the restricted stock units vested on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F2 · derivative.expiration_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016. The remaining 50% of the restricted stock units vested on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| November 05, 2017 Filed Nov 6, 2017 21:09 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-059399 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:39 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-17-005327 · doc4.xml · derivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-01-19 F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 14, 2016 Filed Nov 15, 2016 21:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,309 | $10.06 | $33,286.22 |
DisclosureSEC source: 0001209191-16-150139 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,691 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.05 to $10.13, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2016 Filed Nov 8, 2016 21:13 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-148848 · doc4.xml · derivative · entry 2 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F2 · derivative.exercise_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F2 · derivative.expiration_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| November 05, 2016 Filed Nov 8, 2016 21:13 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-148848 · doc4.xml · nonDerivative · entry 1 Frenkel Ran · CIK 0001623108 · Chief Dev Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.